Payment overview · 2025
General Payments
$373.88
18 reported records · 7 companies
Healthcare provider profile · identity verified
John P Williams, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · WILLITS, CA · NPI 1144220369
Verified facts
What the public records show
CMS Open Payments records show John P Williams, D.O. received $373.88 in general payments during 2025 across 18 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 33.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Jardiance, Kerendia, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Jardiance by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $125.60 | 33.6% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $106.60 | 28.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.04 | 13.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.59 | 9.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.52 | 5.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.02 | 4.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.51 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $373.88 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $125.60 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $106.60 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $106.60 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $52.04 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.59 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 159 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 147 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
159 | 29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
159 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
147 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 442 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 429 | 87 |
| Gabapentin | Gabapentin | 399 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 377 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 305 | 58 |
| Oxycodone Hcl | Oxycodone Hcl | 277 | 35 |
| Furosemide | Furosemide | 275 | 53 |
| Metformin Hcl | Metformin Hcl | 261 | 66 |
| Potassium Chloride | Potassium Chloride | 246 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 225 | 47 |
| Losartan Potassium | Losartan Potassium | 221 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 51 |
| Ropinirole Hcl | Ropinirole Hcl | 214 | 30 |
| Eliquis | Apixaban | 205 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 201 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 56 |
| Quetiapine Fumarate | Quetiapine Fumarate | 163 | 26 |
| Jardiance | Empagliflozin | 159 | 29 |
| Prednisone | Prednisone | 156 | 68 |
| Lisinopril | Lisinopril | 150 | 45 |
| Ozempic | Semaglutide | 147 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 31 |
| Mirtazapine | Mirtazapine | 136 | 33 |
| Alendronate Sodium | Alendronate Sodium | 133 | 25 |
| Omeprazole | Omeprazole | 133 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 27 |
| Trazodone Hcl | Trazodone Hcl | 123 | 25 |
| Montelukast Sodium | Montelukast Sodium | 116 | 23 |
| Sertraline Hcl | Sertraline Hcl | 95 | 15 |
| Tramadol Hcl | Tramadol Hcl | 92 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 21 |
| Famotidine | Famotidine | 83 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 17 |
| Meloxicam | Meloxicam | 81 | 20 |
| Carvedilol | Carvedilol | 80 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 80 | 13 |
| Ezetimibe | Ezetimibe | 79 | 14 |
| Baclofen | Baclofen | 71 | 17 |
| Celecoxib | Celecoxib | 69 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 13 |
| Spironolactone | Spironolactone | 67 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 66 | suppressed |
| Allopurinol | Allopurinol | 61 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 17 |
| Lorazepam | Lorazepam | 54 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 14 |
| Ibuprofen | Ibuprofen | 51 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 16 |
| Diazepam | Diazepam | 46 | 13 |
| Metformin Hcl Er | Metformin Hcl | 46 | suppressed |
| Methadone Hcl | Methadone Hcl | 46 | suppressed |
| Pregabalin | Pregabalin | 46 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 45 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 45 | suppressed |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 31 |
| Nortriptyline Hcl | Nortriptyline Hcl | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 40 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 38 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | 12 |
| Finasteride | Finasteride | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 37 | 12 |
| Azithromycin | Azithromycin | 36 | 32 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 17 |
| Clonidine Hcl | Clonidine Hcl | 34 | 12 |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 22 |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Risperidone | Risperidone | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 11 |
| Fluconazole | Fluconazole | 15 | 11 |
| Lactulose | Lactulose | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Caplyta | Lumateperone Tosylate | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $373.88 · 18 records | Bayer Healthcare Pharmaceuticals Inc. | ABILIFY MAINTENA, CAPLYTA, JARDIANCE, Kerendia, MOUNJARO, Ozempic, Rybelsus, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error